Regulus Therapeutics Inc. RGLS · Stock Open Regulus Therapeutics Inc. in new tab
Regulus Therapeutics Inc. Analysis (RGLS)
Is Regulus Therapeutics Inc. a good investment? Regulus Therapeutics Inc. (RGLS) is currently trading at 8.16 USD.
Investor FAQ
Does Regulus Therapeutics Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Regulus Therapeutics Inc.?
Regulus Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Community Discussion